Workflow
HISOAR(002099)
icon
Search documents
A股公司又现“炒股热”:多家上市公司拟花超10亿炒股
Ge Long Hui A P P· 2025-08-11 09:13
Core Viewpoint - The surge in the Shanghai Composite Index from around 3000 points in April to over 3600 points has led to a noticeable increase in the enthusiasm of listed companies for stock trading, with 57 companies announcing plans to use idle funds for securities investment [1] Group 1: Company Investment Trends - 57 listed companies have announced plans to use their idle funds for securities investment this year [1] - Companies such as Liou Co., Fangda Carbon, Seven Wolves, Tapa Group, Lianfa Co., Xiantan Co., and Zhejiang Yongqiang plan to invest over 1 billion yuan in securities [1] - Liou Co. leads with a proposed investment of 3 billion yuan, while Fangda Carbon and Seven Wolves plan to invest over 2 billion yuan each [1] Group 2: Company Profitability - Most companies engaging in stock trading are from traditional manufacturing sectors such as electric equipment, construction decoration, and steel [1] - Out of the 57 companies, 52 are expected to be profitable in 2024 [1] - The five companies projected to incur losses in 2024 include Buchang Pharma, Haixiang Pharma, Liou Co., Zhongke Jincai, and Baibang Technology [1] Group 3: Notable Losses - Buchang Pharma and Haixiang Pharma are expected to incur significant losses of 550 million yuan and 330 million yuan respectively in 2024, yet they still plan to allocate 30 million yuan and 70 million yuan for securities investment [1]
短线防风险 7只个股短期均线现死叉
Core Viewpoint - The A-share market is experiencing a slight decline, with the Shanghai Composite Index down by 0.28% and a total trading volume of 878.86 billion yuan as of 10:30 AM [1] Group 1: Market Performance - The Shanghai Composite Index is at 3623.70 points, reflecting a decrease of 0.28% [1] - The total trading volume in the A-share market is reported at 878.86 billion yuan [1] Group 2: Moving Averages Analysis - Seven A-shares have seen their 5-day moving averages cross below their 10-day moving averages, indicating potential bearish trends [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Xintai (002294) with a distance of -0.51% - Wanbangde (002082) with a distance of -0.45% - Haixiang Pharmaceutical (002099) with a distance of -0.24% [1] Group 3: Individual Stock Performance - Xintai (002294) is down by 2.07% with a latest price of 47.79 yuan, which is 3.66% below its 10-day moving average [1] - Wanbangde (002082) has decreased by 0.95%, trading at 7.30 yuan, 2.93% below its 10-day moving average [1] - Haixiang Pharmaceutical (002099) is down by 0.33%, with a latest price of 6.08 yuan, 1.95% below its 10-day moving average [1] - Other stocks such as Bidai Pharmaceutical (688073) and Kewah (002335) also show declines in their respective prices and moving averages [1]
股市必读:海翔药业(002099)8月5日主力资金净流出877.82万元
Sou Hu Cai Jing· 2025-08-05 19:43
Group 1 - The stock price of Haixiang Pharmaceutical (002099) closed at 6.27 yuan on August 5, 2025, with a slight increase of 0.16% and a turnover rate of 0.96% [1] - On August 5, the net outflow of main funds was 877.82 million yuan, while retail investors saw a net inflow of 683.46 million yuan [2][4] - The company announced a share repurchase plan on April 9, 2025, with a total repurchase amount set between 150 million yuan and 300 million yuan, and a maximum repurchase price of 7.46 yuan per share [2] Group 2 - On August 5, 2025, Haixiang Pharmaceutical repurchased 850,000 shares through centralized bidding, accounting for 0.05% of the total share capital, with a total transaction amount of 5,326,664 yuan [2][4] - The company plans to continue the repurchase based on market conditions and will fulfill its information disclosure obligations [2]
海翔药业: 关于首次回购公司股份的公告
Zheng Quan Zhi Xing· 2025-08-05 16:20
Group 1 - The company Zhejiang Haixiang Pharmaceutical Co., Ltd. has approved a share repurchase plan using its own funds, with a total repurchase amount between RMB 150 million and RMB 300 million, and a maximum repurchase price of RMB 7.46 per share [1][2] - The first share repurchase involved buying back 850,000 shares, which represents 0.05% of the company's total share capital, with a total transaction amount of RMB 5,326,664, at prices ranging from RMB 6.24 to RMB 6.29 per share [1][2] - The repurchase plan is in compliance with relevant laws and regulations, and the company will continue to implement the plan based on market conditions within the specified timeframe [2]
海翔药业:8月5日回购公司股份850000股
Zheng Quan Ri Bao Wang· 2025-08-05 12:42
证券日报网讯8月5日晚间,海翔药业(002099)发布公告称,2025年8月5日,公司首次通过股票回购专 用证券账户以集中竞价交易方式回购公司股份850,000股,占公司总股本的0.05%。 ...
海翔药业:首次回购85万股
Mei Ri Jing Ji Xin Wen· 2025-08-05 09:57
Group 1 - Company HaiXiang Pharmaceutical announced a stock buyback of 850,000 shares, representing 0.05% of its total share capital, with a total transaction amount of approximately 5.33 million RMB [2] - The buyback occurred on August 5, 2025, with a maximum transaction price of 6.29 RMB per share and a minimum price of 6.24 RMB per share [2] Group 2 - For the year 2024, the revenue composition of HaiXiang Pharmaceutical is as follows: 70.59% from the pharmaceutical manufacturing sector, 28.47% from the dye industry, and 0.94% from other sources [2]
海翔药业(002099.SZ):首次回购85万股 耗资532.666万元
Ge Long Hui A P P· 2025-08-05 09:18
格隆汇8月5日丨海翔药业(002099.SZ)公布,2025年8月5日,公司首次通过股票回购专用证券账户以集 中竞价交易方式回购公司股份85万股,占公司总股本的0.05%,最高成交价为6.29元/股,最低成交价为 6.24元/股,成交总金额为532.6664万元人民币(不含交易费用)。 ...
海翔药业:首次回购0.05%公司股份
Xin Lang Cai Jing· 2025-08-05 09:05
海翔药业公告,2025年8月5日,公司首次通过股票回购专用证券账户以集中竞价交易方式回购公司股份 85万股,占公司总股本的0.05%,最高成交价为6.29元/股,最低成交价为6.24元/股,成交总金额为 532.67万元人民币(不含交易费用)。本次回购符合相关法律法规的要求,符合既定的回购方案。 ...
海翔药业(002099) - 关于首次回购公司股份的公告
2025-08-05 09:02
证券代码:002099 证券简称:海翔药业 公告编号:2025-035 浙江海翔药业股份有限公司 关于首次回购公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司(以下简称"公司")于 2025 年 4 月 9 日召开 第七届董事会第十三次会议,审议通过了《关于回购股份方案的议案》,同意公 司使用自有/自筹资金以集中竞价交易方式回购部分公司股票(以下简称"本次 回购"),在未来适宜时机用于股权激励或者员工持股计划。本次回购资金总额 不低于人民币 15,000 万元(含),不超过人民币 30,000 万元(含),回购价格 不超过人民币 7.46 元/股(含)。本次回购的实施期限自董事会审议通过本回购 方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 10 日在《证券时报》 《证券日报》和巨潮资讯网(www.cninfo.com.cn)上披露的《关于回购股份方 案的公告》(公告编号:2025-005)。 一、首次回购公司股份的具体情况 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号— ...
海翔药业股价微涨0.64% 股东户数较上期减少3.22%
Jin Rong Jie· 2025-08-04 18:17
Company Overview - Haisheng Pharmaceutical's latest stock price is 6.26 yuan, an increase of 0.04 yuan from the previous trading day [1] - The stock reached a high of 6.27 yuan and a low of 6.06 yuan during the trading session, with a trading volume of 188,012 hands and a transaction amount of 116 million yuan [1] Industry Information - The company operates in the chemical pharmaceutical industry, focusing on the research, development, production, and sales of pharmaceutical raw materials and intermediates [1] - Its product range includes treatments for various fields such as anti-infection, cardiovascular, and mental health [1] Shareholder and Market Data - As of July 31, 2025, the number of shareholders for Haisheng Pharmaceutical is 30,100, a decrease of 1,001 from the previous period [1] - The average number of circulating shares held per shareholder increased from 52,000 to 53,700 shares, with an average circulating market value of 335,100 yuan [1] - The number of shares held through the Shenzhen Stock Connect is 12.69 million, accounting for 0.78% of the circulating share capital [1] Capital Flow - On August 4, the net outflow of main funds was 13.89 million yuan, representing 0.14% of the circulating market value [1] - Over the past five days, the net inflow of main funds was 354,700 yuan [1]